Compare · KYNB vs NVO
KYNB vs NVO
Side-by-side comparison of Kyntra Bio Inc. (KYNB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KYNB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 8001.7x KYNB ($21.7M).
- Over the past year, KYNB is down 56.6% and NVO is down 30.4% - NVO leads by 26.3 points.
- KYNB has been more active in the news (6 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for KYNB).
- Company
- Kyntra Bio Inc.
- Novo Nordisk A/S
- Price
- $4.93-12.74%
- $38.82-1.05%
- Market cap
- $21.7M
- $173.66B
- 1M return
- -35.39%
- -10.14%
- 1Y return
- -56.62%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 6
- 3
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KYNB
- Maxim Group initiated coverage on Kyntra Bio with a new price target
- SEC Form 4 filed by Kyntra Bio Inc.
- SEC Form 3 filed by Kyntra Bio Inc.
- SEC Form 8-K filed by Kyntra Bio Inc.
- Kyntra Bio Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
- CEO Wettig Thane covered exercise/tax liability with 209 shares, decreasing direct ownership by 0.77% to 26,796 units (SEC Form 4)
- Chief Financial Officer Delucia David covered exercise/tax liability with 22 shares, decreasing direct ownership by 0.50% to 4,355 units (SEC Form 4)
- Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Kyntra Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank